Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10421)
All Articles published online
|
Publishing Process of This Article
|
Nov 16, 2022 (publication date) through Jan 9, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Huang ML, Shen GT, Li NL. Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment. World J Clin Cases 2022; 10(32): 11690-11701 [PMID: 36405275 DOI: 10.12998/wjcc.v10.i32.11690] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Huang ML, Shen GT, Li NL. Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment. World J Clin Cases 2022; 10(32): 11690-11701 [PMID: 36405275 DOI: 10.12998/wjcc.v10.i32.11690] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i32/11690.htm |
| Number | Citing Articles |
| 1 |
Hongbo Lan, Lina Peng, Fei Chen, Kun Xie, Futing Mu, Jingshuang Wang, Juanjuan Mei, Wenhui Yan. Ubiquitin-specific peptidase 53 suppresses the tumorigenesis of breast cancer cells and its related gene analysis. Molecular and Cellular Probes 2025; 83: 102043 doi: 10.1016/j.mcp.2025.102043
|
| 2 |
Yujing Chen, Jingyi Zhang, Jinfeng Yang, Jiawei Zhao, Xiaotong Guo, Juzheng Zhang, Jinfeng Gan, Weijia Zhao, Siqi Chen, Xinwen Zhang, Yi Lin, Jiamin Jin. Exploring the cancerous nexus: the pivotal and diverse roles of USP39 in cancer development. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-02480-9
|
| 3 |
Wenbiao Xiao, Bingwen Lin, Ying Wang, Peng Huang, Jiandong Lin, Xiongjian Xiao. USP31 PROMOTES THE INFLAMMATORY RESPONSE OF HUMAN LUNG ORGANOIDS TO LIPOPOLYSACCHARIDE TREATMENT. Shock 2025; 63(1): 110 doi: 10.1097/SHK.0000000000002464
|
| 4 |
Kavita Goyal, Muhammad Afzal, Ashok Kumar Bishoyi, R. Roopashree, Suman Saini, R. S. K. Sharma, Piyus Kumar Pathak, Ashish Singh Chauhan, Surendar Aravindhan, Mohd Imran, Abida Abida Abida. Ubiquitin-specific proteases in hepatitis: bridging molecular mechanisms and therapeutic potential. Egyptian Liver Journal 2025; 15(1) doi: 10.1186/s43066-025-00434-y
|
| 5 |
Mohamad Bakkar, Sara Khalil, Komal Bhayekar, Narva Deshwar Kushwaha, Amirreza Samarbakhsh, Sadaf Dorandish, Holly Edwards, Q. Ping Dou, Yubin Ge, Navnath S. Gavande. Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects. Biomolecules 2025; 15(2): 240 doi: 10.3390/biom15020240
|
| 6 |
Suaad Syed, Muhammad Yasir Khan Painda, Dawood Ghafoor, Dongjin Gu, Feng Wang. Physiological roles and therapeutic implications of USP6. Cell Death Discovery 2025; 11(1) doi: 10.1038/s41420-025-02466-0
|
| 7 |
Fatima Haider, Nida Syed, Syeda Abiha Zehra Jaffari, Basir Syed, Aftab Ahmed, Shamshad Zarina, Zehra Hashim. PPA1, TRIM68 and FBXO46: Potential Therapeutic Targets for Triple Negative Breast Cancer. Current Protein & Peptide Science 2025; 26(5): 365 doi: 10.2174/0113892037334325241014053319
|
| 8 |
Lili Kong, Xiaofeng Jin. Dysregulation of deubiquitination in breast cancer. Gene 2024; 902: 148175 doi: 10.1016/j.gene.2024.148175
|
| 9 |
Jicheng Chen, Xinghang Fu, Xiaotan Gao, Yingming Sun, Jian Xiao, Wenxin Chen, Hebing Wang, Binglin Yang, Maoquan Zhang, Yongtian Chen, Yanmei Wen, Hanqing Deng, Changming Chen, Huatian Luo. USP49 promotes the malignancy of triple-negative breast cancer cells by regulating PKMYT1 ubiquitination and stability. Biochemical and Biophysical Research Communications 2026; 797: 153163 doi: 10.1016/j.bbrc.2025.153163
|
| 10 |
Jitendra Gupta, Furqan N. Al-Khateeb, Ahmad Zwenal, Ali G. Alkhathami, Malathi H, Mayank Kundlas, Laxmidhar Maharana, Ashish Singh Chauhan, Yasser Fakri Mustafa, Mohammed Jawad Alnajar. Ubiquitin-specific proteases in pancreatic cancer: Molecular regulators of tumor progression and therapy resistance. Seminars in Oncology 2025; 52(6): 152410 doi: 10.1016/j.seminoncol.2025.152410
|
| 11 |
Sobia Noreen, Umar Bin Kamal, Sara Hasan, Jawaria Iltaf, Fozia Batool, Shazia Akram Ghumman, Tusneem Kausar. Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer. 2025; : 419 doi: 10.1016/B978-0-443-26635-5.00064-X
|
| 12 |
Bo Zhou, Jie Li, Shuai Wu, Haomiao Zhang, Yuanbo Luo, Jingxiang Chen, Geng Chen. USP39/SMC4 promotes hepatoma cell proliferation and 5-FU resistance. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-93029-x
|
| 13 |
Ziqi Chen, Meijun Zhong, Yuhui Lin, Wei Zhang, Yinghong Zhu, Lin Chen, Ziyao Huang, Kaiyuan Luo, Zhifeng Lu, Zhaoqi Huang, Yi Yan. METTL7B-induced histone lactylation prevents heart failure by ameliorating cardiac remodelling. Journal of Molecular and Cellular Cardiology 2025; 202: 64 doi: 10.1016/j.yjmcc.2025.03.006
|
| 14 |
Xiaohan Wang, Sisi Wei, Wanzhao Li, Xiaojian Wei, Cong Zhang, Suli Dai, Ming Ma, Lianmei Zhao, Baoen Shan. P-Hydroxylcinnamaldehyde induces tumor-associated macrophage polarization toward the M1 type by regulating the proteome and inhibits ESCC in vivo and in vitro. International Immunopharmacology 2023; 119: 110213 doi: 10.1016/j.intimp.2023.110213
|
| 15 |
Danielle Whitham, Pathea Bruno, Norman Haaker, Kathleen F. Arcaro, Brian T. Pentecost, Costel C. Darie. Deciphering a proteomic signature for the early detection of breast cancer from breast milk: the role of quantitative proteomics. Expert Review of Proteomics 2024; 21(1-3): 81 doi: 10.1080/14789450.2024.2320158
|
| 16 |
Chenchen Hu, Wenzhi Tian, Yun Tang, Peiran Wang, Tiantian Kuan, Wei Wei, Dong Chen, Peng Li, Xi Su. USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAFV600E-mutant thyroid cancer via ferroptosis. Biochemical Pharmacology 2026; 243: 117522 doi: 10.1016/j.bcp.2025.117522
|
| 17 |
Venkateshwaran Krishnaswami, Borish Loushambam, S.A. Jacob Raja, Himika Salam, Munish Kumar, Sivakumar Vijayaraghavalu. Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer. 2025; : 439 doi: 10.1016/B978-0-443-26635-5.00060-2
|
| 18 |
Guangce Xia, Yulin Guo, Jiajia Zhang, Meng Han, Xiangchao Meng, Ji Lv. An Overview of the Deubiquitinase USP53: A Promising Diagnostic
Marker and Therapeutic Target. Current Protein & Peptide Science 2024; 25(9): 708 doi: 10.2174/0113892037292440240518194922
|
| 19 |
Pisong Li, Xiaoyu Zhu, Hui Qu, Zhongbin Han, Xingyu Yao, Yuan Wei, Baijun Li, Hongshen Chen. Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells. OncoTargets and Therapy 2024; : 741 doi: 10.2147/OTT.S463217
|